07 Jan 2001

Polygynax® (Polygynax® Vaginalkapseln) - Deutschland

Updated: 07 Jan 2001

Polygynax®

Purulente Fluor, Vaginalmykosen, Vulvitis.

Polygynax® Description, Presentation and Dosage

Polygynax® Description

Polygynax® Drug Class Description

Kombinationen mit Antibiotika u./od. Antimykotika

Polygynax® Drug Description

1 Vaginalkps. enth.: Neomycin 35 000 I.E. Nystatin 100 000 I.E. Polymyxin-B-sulfat 35 000 I.E.

Polygynax® Generic Name

Polygynax® Vaginalkapseln

Polygynax® Presentation

Polygynax® Presentation

Polygynax®

Polygynax® Manufacturer

UCB

Related Learning Zones

LAL-D Knowledge Centre

LAL-D Knowledge Centre

The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.

Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH

Obesity CME series

Obesity CME series

This European Obesity Initiative CME series contains three online modules, which are ideal for healthcare professionals looking to widen their understanding of obesity as a serious medical illness. Each module is EACCME-accredited and free to complete. Successful completion of the series will earn participants a combined total of 5 European CME credits (ECMECs).

Polygynax® Dosage

Polygynax® Adult Dosage

Glycerid aus Palmöl, Hydriertes Sojaöl, Dimeticon, Gelatine, Glycerol, Kaliumsorbat.

Polygynax® Precautions, Reactions and Contraindications

Polygynax® Special Precautions

Related Drugs - Women's Health and Obs/Gyn

Back to top